26 March 2026
EMADOC-1700519818-2992694
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion[1] (post authorisation)

Retsevmo

selpercatinib

On 26 March 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Retsevmo. The marketing authorisation holder for this medicinal product is Eli Lilly Nederland B.V.

The CHMP adopted changes to the existing indications as follows:[2]

Retsevmo as monotherapy is indicated for the treatment of adults with:

- Advanced *RET* fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a *RET* inhibitor. **For biomarker-based patient selection, see section 4.2.**
- ~~advanced *RET* fusion, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted (see sections 4.4 and 5.1)~~

Retsevmo as monotherapy is indicated for the treatment of adults and ~~adolescents~~ **paediatric patients ~~1~~2 years of age** and older with:

- advanced *RET* fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate). **For biomarker-based patient selection, see section 4.2.**
- advanced *RET*-mutant medullary thyroid cancer (MTC). **For biomarker-based patient selection, see section 4.2.**
- **advanced *RET* fusion-positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted (see sections 4.4 and 5.1). For biomarker-based patient selection, see section 4.2.**

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to

[1] Summary of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion
[2] New text in bold, removed text as strikethrough

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

the marketing authorisation has been granted by the European Commission.